Latest news with #CFOoftheYear
Business Journals
22-07-2025
- Business
- Business Journals
City of Boston CFO Ashley Groffenberger named BBJ CFO of the Year Rising Star honoree
There are a lot of variables when it comes to being the chief financial officer for the city of Boston. In addition to overseeing and developing the budget, there's a five-year capital plan that needs to be created and revised, assessments, payment collections and managing the treasury. It's safe to say that the job comes with its share of stresses. Sometimes, there are so many moving pieces that Ashley Groffenberger wishes her team could simplify it all and just turn everything into an easy math equation. Which is exactly why her staff got her an algebra workbook, which she keeps on her desk. 'When we're dealing with these really difficult decisions, I sometimes look at my team and I'm like, 'I wish we could just sit here and solve for X,'" said Groffenberger. "When I need to decompress, I solve for X. That's how I unwind.' Groffenberger's career has been filled with more constants than variables. Since graduating from Northeastern in 2010, she has been working in government finance, seeking a mission-driven organization that has a tangible impact on the surrounding community. That goal led her from her initial role as an analyst in the State House to her current role at City Hall. And most recently, Groffenberger has been named the 2025 Rising Star awardee at the Boston Business Journal's CFO of the Year awards. Coming into the position was somewhat familiar for Groffenberger. She had spent the past eight years in California's Bay Area, where she worked as the budget director for the city and county of San Francisco for seven of those eight years. The time in San Francisco helped prepare her for her role with the city of Boston — and the Dunkin' Donuts that opened an hour away from her San Fransisco office offered a small reminder of home. After Michelle Wu 's successful bid to become the mayor of Boston in 2021, Groffenberger's name was floated as a potential candidate for the CFO role. When Wu's administration reached out with an offer, Groffenberger called the decision to return to the place she once thought of as the apex of the world a 'no-brainer.' 'I like to think about the dream jobs I have, and it was always a really short list,' said Groffenberger. 'This job was always at the top of that list.' The job is not without its variables, probably more than most people realize she says. Groffenberger says that a major misconception people have about the job of CFO is that it's easy to find solutions, or that it's just a matter of allocating funds. In reality, the job involves an 'incredible amount' of consideration and analysis before making a decision. When you have more than one variable to solve for, things can get complicated. But Groffenberger knows she isn't going at it alone. She makes it a point to acknowledge the significant contributions her team makes to her overall success and the success of the city. 'I will attribute all of my success to the people that I work with. I mean, this job is not singular,' Groffenberger said. 'So I attribute it to the team and the leadership here in the city, for you know, the success that we all enjoy.'
Business Journals
03-06-2025
- Business
- Business Journals
May M&A: GSK, Sanofi and Lookout Inc.
CFO of the Year Join us for our 17th annual CFO of the Year awards program honoring the 2025 CFO's of the Year!
Yahoo
21-05-2025
- Business
- Yahoo
Freenome Appoints Linh H. Le as Chief Financial Officer
Seasoned diagnostics executive brings expertise in financial strategy and operational infrastructure development across diagnostics and Medtech industries BRISBANE, Calif., May 21, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Linh H. Le as its new chief financial officer. Linh brings more than two decades of experience in leading finance and operations across diagnostics and Medtech companies, including Ambry Genetics, Medtronic and Predicine. At Freenome, Linh will oversee financial strategy and operational execution, supporting the company as it expands its commercial footprint. "Linh has a proven track record of building the financial and operational foundations required to scale and sustain innovation," said Aaron Elliott, Ph.D., chief executive officer of Freenome. "He has led large-scale transformations, improved enterprise performance, and brings a focused, results-oriented approach that will help us execute with precision and purpose. I'm thrilled to welcome him to Freenome's leadership team." Prior to joining Freenome, Linh served as CFO at Predicine, where he implemented a best-in-class revenue cycle management system and led expansion into multiple U.S. markets. He previously held the role of chief operating officer at Ambry Genetics, where he led organization-wide change that supported significant sample volume growth and operational scalability. Earlier in his career, Linh spent 14 years at Medtronic Diabetes, where he served as CFO for the intensive insulin management business unit with oversight across North America, EMEA, and Asia-Pacific. Linh began his career in assurance practice at KPMG and management advisory practice at PwC before taking on leadership roles at The Walt Disney Company and Fox. He is a Certified Public Accountant, holds a Bachelor of Science in Business Administration and Accounting from California State University, Northridge, and completed executive coursework at the Wharton School of Business. He was named CFO of the Year by the Los Angeles Times in 2022. About FreenomeFreenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the disease's inherent heterogeneity. Freenome's multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer's subtlest cues, even at the earliest stages of the disease. With the convenience of a standard blood draw, Freenome aims to empower everyone to access recommended cancer screenings. The company is partnering with healthcare organizations and population health decision-makers to integrate its technology and software platform, making cancer detection easier and more accessible. Freenome is headquartered in Brisbane, California. Find out more at and visit us on LinkedIn. View original content to download multimedia: SOURCE Freenome Holdings, Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
21-05-2025
- Business
- Associated Press
Freenome Appoints Linh H. Le as Chief Financial Officer
Seasoned diagnostics executive brings expertise in financial strategy and operational infrastructure development across diagnostics and Medtech industries BRISBANE, Calif., May 21, 2025 /PRNewswire/ -- Freenome, a biotechnology company pioneering an early cancer detection platform, today announced the appointment of Linh H. Le as its new chief financial officer. Linh brings more than two decades of experience in leading finance and operations across diagnostics and Medtech companies, including Ambry Genetics, Medtronic and Predicine. At Freenome, Linh will oversee financial strategy and operational execution, supporting the company as it expands its commercial footprint. 'Linh has a proven track record of building the financial and operational foundations required to scale and sustain innovation,' said Aaron Elliott, Ph.D., chief executive officer of Freenome. 'He has led large-scale transformations, improved enterprise performance, and brings a focused, results-oriented approach that will help us execute with precision and purpose. I'm thrilled to welcome him to Freenome's leadership team.' Prior to joining Freenome, Linh served as CFO at Predicine, where he implemented a best-in-class revenue cycle management system and led expansion into multiple U.S. markets. He previously held the role of chief operating officer at Ambry Genetics, where he led organization-wide change that supported significant sample volume growth and operational scalability. Earlier in his career, Linh spent 14 years at Medtronic Diabetes, where he served as CFO for the intensive insulin management business unit with oversight across North America, EMEA, and Asia-Pacific. Linh began his career in assurance practice at KPMG and management advisory practice at PwC before taking on leadership roles at The Walt Disney Company and Fox. He is a Certified Public Accountant, holds a Bachelor of Science in Business Administration and Accounting from California State University, Northridge, and completed executive coursework at the Wharton School of Business. He was named CFO of the Year by the Los Angeles Times in 2022. About Freenome Freenome is breaking barriers to early cancer detection with a suite of blood tests built on its multiomics platform. The company recognizes that no single technology can identify every cancer due to the disease's inherent heterogeneity. Freenome's multimodal approach combines molecular biology and assays with computational biology, machine learning and multiple data types to tune into cancer's subtlest cues, even at the earliest stages of the disease. With the convenience of a standard blood draw, Freenome aims to empower everyone to access recommended cancer screenings. The company is partnering with healthcare organizations and population health decision-makers to integrate its technology and software platform, making cancer detection easier and more accessible. Freenome is headquartered in Brisbane, California. Find out more at and visit us on LinkedIn. View original content to download multimedia: SOURCE Freenome Holdings, Inc.
Business Journals
20-05-2025
- Business
- Business Journals
BBJ CFO of the Year lifetime achievement, rising star honorees named
The Boston Business Journal has named the F. Gorham Brigham Lifetime Achievement Award and Rising Star honorees for its CFO of the Year program for 2025.
